P-BCMA-ALLO1, an allogeneic CAR-T cell therapy, has shown a 91% overall response rate in a Phase 1a trial for relapsed/refractory multiple myeloma. It uses healthy donor T-cells and targets the BCMA protein on myeloma cells...allogenic means lots less expensive, which is always a great thing! OK it's not prostate but I am always happy to see good news
Not prostate cancer related (but Phas... - Advanced Prostate...
Not prostate cancer related (but Phase 1b): allogenic CAR-T therapy is having good results in multiple myeloma!
Written by
Maxone73
To view profiles and participate in discussions please or .
5 Replies
•
isn't Tanya Dorf of Duke trialing the Car-t therapy?
Right but it’s a different kind of car-t therapy. This one is allogenic, which basically means off the shelf….which translates into lower costs and less time between the decision making to treat and the treatment itself as they don’t need to “grow” the cells starting from your own 😀
if we want to stay positive, currently there are 150 companies trying 166 different ways to fight prostate cancer…of course not all are for advanced cancer, but I am talking about clinical trials only….can we hope to have at least 5 new and working therapies within the next 2-3 years? 😃
Not what you're looking for?
You may also like...
CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer
A few years off but one to keep an eye on.
CAR T-Cell Use Possible in Metastatic...
Phase 1 trial: Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers, no prostate cancer but very interesting
Oncolytic viruses are promising! Prostate cancer is a solid tumor with an immune suppressing micro...
not PCa related but promising in vivo therapy for cancer metastasis
”The polymer eliminates colorectal cancer liver metastases and prolongs mice survival, after only a...
Cancer and stress: not directly related to prostate cancer but interesting research
Being on melatonin and some chemical stuff to be able to sleep at night, I do not have anything...
Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing
This is what I was working on getting for my husband the day before he died last month. They're...
Related Posts
A question about the immune system - Trial Decision Time
Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?
CD19 CAR-T cell therapy for B-ALL achieved remarkable efficacy with a complete remission of 70–90%
PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer
